What is Electromed Inc?
develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.
ELMD · Verdict
Strong reward · low risk
ELMD scores well on balance sheet and volatility with no major weaknesses flagged in the model.
Based on 88% data coverage
ELMD · Verdict
Current ratio 4.31
Top decile vs peers
12% net margin · 20% ROE
17% free-cash-flow margin
Rev +15.4% CAGR · earnings +48.4%
Model-based scoring. For information only — not financial advice.
develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. The company is listed on the NYSE MKT in USA, operating in the Healthcare sector, with a market capitalisation of 193.08M, and a P/E ratio of 23.6x.
The scoring profile indicates a strong reward potential, driven primarily by profitability and growth. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.